🦊/Companies

Manus Bio

Augusta, US · Founded 2011 · Delaware corporation · 189 employees on LinkedIn · 9 known investors

Find your way into Manus Bio

Manus Bio uses industrial biotechnology and engineered microbial cell factories to produce "BioAlternatives" — sustainable versions of molecules normally sourced from petrochemicals, agriculture, or animal husbandry — and offers a scale-up platform covering cell factory design through biomanufacturing. Its products include sweeteners and flavor/fragrance ingredients supplied to food and consumer goods companies such as Tate & Lyle and Givaudan.

Founders & leadership

Manus Bio was founded in 2011 by Ajikumar Parayil, Aji Parayil, and Greg Stephanopoulos.

APAjikumar Parayil
Ajikumar ParayilinFounder and CEO
APAji Parayil
Aji ParayilinCo-founder
GS
Greg StephanopoulosCo-founder

Board

JWJason Whaley
Jason WhaleyinCEO2011–2016General Partner at Rhapsody Venture Partners
CBCarsten Boers
Carsten BoersinBoard member2012–2018Managing Partner at Rhapsody Venture Partners
RG
Richard GoldsteinBoard director

Investors · 9

Reported raises · per SEC filings

Form D private placements

$118M disclosed across 6 rounds · 2016–2024

$11.3MraisedMay 2024 · 6 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Ajikumar Parayil KumaranDirector, Executive Officer
  • Rick GersonDirector
  • Alena IvashenkaDirector
  • Julio A. Ruiz CalderonExecutive Officer
  • Michael CarlosDirector
  • Jean NehmeDirector
Offering amount
$11.3M
Amount sold
$11.3M
First sale
Apr 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$21.2MraisedMay 2023 · 14 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • John NehmeDirector
  • Michael CarlosDirector
  • Jeremiah HuxExecutive Officer
  • Ajikumar ParayilExecutive Officer, Director
  • Rick GersonDirector
  • Alena IvashenkaDirector
Offering amount
$22.3M
Amount sold
$21.2M
First sale
Aug 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$66.2MraisedNov 2020 · 27 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Gregory StephanopoulosDirector
  • Zanna McFersonDirector
  • Raymond ChangDirector
  • Bryon AlsbergDirector
  • Michael CarlosDirector
  • Colin GoundenDirector
  • Christine SantosExecutive Officer
  • Paul BoniExecutive Officer
  • Jeff AndersonExecutive Officer
  • Ajikumar ParayilExecutive Officer, Director
Offering amount
$80M
Amount sold
$66.2M
First sale
Apr 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$10MraisedJul 2018 · 15 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Paul BoniExecutive Officer
  • Zanna McFersonDirector
  • Michael CarlosDirector
  • Gregory StephanopoulosDirector
  • Colin GoundenDirector
  • Raymond ChangDirector
  • Ajikumar ParayilExecutive Officer, Director
  • Bryon AlsbergDirector
  • Christine SantosExecutive Officer
  • Jeff AndersonExecutive Officer
Offering amount
$12M
Amount sold
$10M
First sale
Jun 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$9.1MraisedDec 2017 · 24 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Byron AlsbergDirector
  • Michael CarlosDirector
  • Colin GoundenDirector
  • Carsten BoersDirector
  • Gregory StephanopoulosDirector
  • Ajikumar ParayilExecutive Officer, Director
Offering amount
$10M
Amount sold
$9.1M
First sale
Aug 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$300KraisedOct 2016 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Richard GoldsteinDirector
  • Jason WhaleyDirector
  • Carsten BoersDirector
  • Ajikumar ParayilExecutive Officer, Director
  • Gregory StephanopoulosDirector
Offering amount
$3M
Amount sold
$300K
First sale
Sep 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap

Companies competing with Manus Bio for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 6 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
Department of Agriculture (USDA)Phase I2018$99K
National Science FoundationPhase II2017$600K
National Science FoundationPhase I2016$225K
National Science FoundationPhase ISTTR2013$225K
National Science FoundationPhase I2013$150K
National Science FoundationPhase I2012$150K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Manus Bio do?
Manus Bio uses industrial biotechnology and engineered microbial cell factories to produce "BioAlternatives" — sustainable versions of molecules normally sourced from petrochemicals, agriculture, or animal husbandry — and offers a scale-up platform covering cell factory design through biomanufacturing. Its products include sweeteners and flavor/fragrance ingredients supplied to food and consumer goods companies such as Tate & Lyle and Givaudan.
Who founded Manus Bio?
Manus Bio was founded by Ajikumar Parayil, Aji Parayil, Greg Stephanopoulos in 2011.
Who are Manus Bio's investors?
Manus Bio's investors include +ND Capital, Civilization Ventures Management, Llc, Energy Impact Partners, Liebenthal Ventures, Nelstone Ventures, NXT Ventures, Prefix Capital, Rhapsody Venture Partners and 1 more.
How much funding has Manus Bio raised?
Manus Bio has disclosed $118M raised across 6 rounds.
Where is Manus Bio headquartered?
Manus Bio is headquartered in Augusta, US.